Alkermes’ alixorexton posts positive Phase 2 Vibrance-1 results in narcolepsy type 1 study

• Alkermes reported publication of positive Phase 2 Vibrance-1 results for alixorexton in adults with narcolepsy type 1 in The Lancet Neurology.
• Results were previously announced, not newly presented, showing improved daytime wakefulness and sleepiness measures versus placebo.
• Study also indicated reduced cataplexy at one dose, with broader patient-reported benefits in daily functioning.
• Safety profile appeared generally well tolerated, with mostly mild-to-moderate adverse events and no serious treatment-emergent events reported.
• Positive Phase 2 readouts supported the launch of the global Phase 3 Brilliance program testing once-daily and split-dose regimens in narcolepsy types 1 and 2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alkermes plc published the original content used to generate this news brief via Business Wire (Ref. ID: 20260824378408) on August 24, 2026, and is solely responsible for the information contained therein.